Overview
3BIO helps biotech companies, pharma, agritech, and research institutions navigate complex legal frameworks across three integrated regulatory pillars: biodiversity (Access and Benefit Sharing laws), biosafety (biorisk management, permits, compliance), and biotech regulatory (regulatory analysis, market authorization, post-market compliance). The consultancy operates in Ghent, Belgium with 18 multidisciplinary professionals and 20+ years of combined expertise.
Key people
In the news
- New Genomic Techniques: the regulatory path takes its next steps The 2018 ruling of the Court of Justice of the European Union — which confirmed plants obtained through targeted mutagenesis to be within the scope of the GMO rules — was widely regarded as scientifically flawed and triggered years of legislative debate. On 17 June 2026, the European Parliament and the Council adopted new rules for plants obtained by targeted mutagenesis and cisgenesis, and for their food and feed products. The rules entered into force on 16 July
- First stop at GA2026 in Reims for 3BIO's co-founder/Chief Legal Officer Dominic Muyldermans and legal associate Bruna Maia! They kicked off the trip at the pre-congress workshop, 𝑨𝒄𝒄𝒆𝒔𝒔 𝑩𝒆𝒏𝒆𝒇𝒊𝒕 𝑺𝒉𝒂𝒓𝒊𝒏𝒈 𝒊𝒏 𝑵𝒂𝒕𝒖𝒓𝒂𝒍 𝑷𝒓𝒐𝒅𝒖𝒄𝒕 𝑹𝒆𝒔𝒆𝒂𝒓𝒄𝒉: 𝑭𝒓𝒐𝒎 𝒄𝒉𝒂𝒍𝒍𝒆𝒏𝒈𝒆𝒔 𝒕𝒐 𝒃𝒆𝒔𝒕 𝒑𝒓𝒂𝒄𝒕𝒊𝒄𝒆𝒔?, co-chaired by Dominic, as part of the 74th congress of the Society for Medicinal Plant and Natural Product Research (GA). ABS is the set of rules, under the Convention on Biological Diversity and the
- Innovation in biological crop protection is advancing rapidly. But existing legal frameworks are not fully aligned with the underlying technologies. Companies bringing these innovations to market face challenges at the intersection of intellectual property and regulation. And these challenges are not limited to a single jurisdiction. They occur across major markets, including the European Union, the United States, Brazil and China. On 23 October in Basel, this expert conference brings the intellectual property and regulatory
- For most biosafety professionals, the "Guidelines for Research Involving Recombinant DNA Molecules," issued by the U.S. National Institutes of Health, have served as a solid reference for biosafety management for nearly fifty years. The NIH has now published a Request for Comment on a draft NIH Biosafety Policy for Research Involving Biohazards, which would substantially broaden the scope of NIH oversight beyond recombinant and synthetic nucleic acid research to also cover wild-type biological agents, genetically modified organisms
- Innovation in biological crop protection is facing challenges at the crossroads of regulatory and IP frameworks. This stems from a lack of alignment between the technological developments and these frameworks, and it plays out across every major market, from the EU and the US to Brazil and China. This will be addressed at the expert conference 𝑼𝒏𝒍𝒐𝒄𝒌𝒊𝒏𝒈 𝑩𝒊𝒐𝒍𝒐𝒈𝒊𝒄𝒂𝒍 𝑪𝒓𝒐𝒑 𝑷𝒓𝒐𝒕𝒆𝒄𝒕𝒊𝒐𝒏: 𝑵𝒂𝒗𝒊𝒈𝒂𝒕𝒊𝒏𝒈 𝑰𝑷 & 𝑹𝒆𝒈𝒖𝒍𝒂𝒕𝒐𝒓𝒚 𝑰𝒔𝒔𝒖𝒆𝒔 in Basel on 23 October. The conference is co-chaired by
- 3BIO was represented at European Congress of Biotechnology (ECB) 2026 in Antwerp this week, where two of our team members took the stage to present their work. Lisanne Terrie presented "Promise or puzzle? Assessing whether NGT laws truly ease gene editing" as part of Symposium 8: Gene Editing for Crop Improvement. The presentation assessed whether the EU's proposed New Genomic Techniques (NGT) framework will genuinely simplify the regulatory landscape for gene-edited crops, or whether significant legal and practical challenges
- 𝗪𝗲𝗹𝗰𝗼𝗺𝗲 𝘁𝗼 𝘁𝗵𝗲 𝘁𝗲𝗮𝗺, 𝗦𝘁𝗲𝗳𝗮𝗻𝗶𝗲! We are delighted to formally introduce Stefanie Verstringe, the newest member of the 3BIO team. From chocolate to biosafety, Stefanie's career path has been a unique one. She holds a degree in Bio-engineering in Applied Biological Sciences and a PhD from Ghent University on the crystallisation behaviour of palm oil. Afterward, she moved into the animal feed industry, where she led a research laboratory working with pathogens as Innolab Manager at Agrifirm. We are very much
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.